What's the most attractive weight-loss stock right now? We asked Seeking Alpha analysts Edmund Ingham, Stephen Ayers and Oneil Trader for their picks. Read more here.

We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...

All lines have been placed on mute to prevent any background noise. There will be a question-and-answer session at the ...

Researchers have discovered a method to induce chirality in non-chiral materials using terahertz light. This groundbreaking ...

Can include rhythm, melody, harmony, dynamics, texture, timbre and structure. of the music such as their melody close melodyDifferent pitched notes played one after another making a tune., ...

Gastrointestinal adverse events partially mediated the weight loss effects among patients with obesity who received tirzepatide vs placebo.

Novo Nordisk today announced 2024 earnings, reporting a 26% increase in annual sales to ~$40.56bn. Read why I upgrade NVO ...

The rationale for the study, according to the authors, is that “Nearly 2% of the US population received a prescription for ...

Results from a case series identified a potential association between ophthalmic complications and the rapid correction of hyperglycemia, brought on by patients using either semaglutide or tirzepatide ...

“Each injection is painful.” In a recent study, researchers explored if diabetes and obesity drug tirzepatide (the active ingredient in Zepbound and Mounjaro) could improve CGL, as it improves ...

Obesity medication prescriptions reached 1.5 million, driven by GLP-1 agents semaglutide and tirzepatide, as public interest ...

Early findings suggest that tirzepatide – used for diabetes and obesity – significantly improves blood glucose levels in CGL patients. If confirmed in larger studies, this treatment could provide a ...